文献速递衰弱、肌少症与跌倒老年综合评估

DNA甲基化时钟测量的生物学年龄与衰弱的系统综述与荟萃分析

Biological age measured by DNA methylation clocks and frailty: a systematic review and meta-analysis.
PubMed 文献 · Lancet Healthy Longev · 2025-11-06

横断面分析中Hannum、PhenoAge、GrimAge的表观遗传年龄加速及衰老速度均与较高衰弱显著相关;纵向分析仅GrimAge表观遗传年龄加速与衰弱增加显著相关。

要点

  • 横断面中Hannum、PhenoAge、GrimAge表观遗传年龄加速及衰老速度均与较高衰弱显著相关。
  • 纵向分析仅GrimAge表观遗传年龄加速与衰弱增加显著相关。
  • DNA甲基化年龄和年龄偏差与衰弱无显著关联。

核心结论

  • 较高的GrimAge表观遗传年龄加速与较高衰弱一致相关。

关键数值与推荐

  • DNA甲基化年龄和年龄偏差与衰弱无显著关联。

临床怎么用

  • GrimAge表观遗传年龄加速可作为识别衰弱风险个体的候选生物标志物,但尚需在大型协调纵向队列中开发与验证专门预测衰弱的DNA甲基化时钟后方可转化至临床。

局限性

  • 纳入研究以横断面为主(17项横断面、1项纵向、6项兼有),纵向证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frailty is an age-related condition characterised by multisystem physiological decline, which increases vulnerability to adverse outcomes. Biomarkers of ageing might identify individuals at risk and enable early interventions. This systematic review and meta-analysis aimed to examine cross-sectional and longitudinal associations between DNA methylation-based biological age metrics (eg, DNA methylation age, epigenetic-age acceleration [EAA], and age deviation) and frailty. METHODS: In a systematic search of six databases (Embase, Cochrane Central Register of Controlled Trials, PubMed, Ovid, Scopus, and Web of Science) from Jan 1, 2011, to June 6, 2025, we identified population-based cohort studies reporting associations between DNA methylation age, EAA, or age deviation and frailty from general or disease-specific populations with a control group. Risk of bias was assessed using an adapted Newcastle-Ottawa Scale. Random-effects meta-analyses with Hartung-Knapp adjustments were performed on standardised β coefficients and SEs. Publication bias, influence, and sensitivity analyses were conducted. FINDINGS: From 34 437 records screened, 24 studies met the inclusion criteria (17 cross-sectional studies, one longitudinal study, and six studies that were both cross-sectional and longitudinal), encompassing 28 325 participants (14 757 [52·1%] female; median of mean age 65·2 years [IQR 62·2-69·4]). DNA methylation age and age deviation showed no association with frailty. In cross-sectional meta-analyses, higher Hannum EAA (nine studies; n=11 162; standardised β coefficient 0·06 [95% CI 0·02-0·09], I2=71·4%), PhenoAge EAA (eight studies; n=10 371; 0·07 [0·03-0·11], I2=81·7%), GrimAge EAA (eight studies; n=10 371; 0·11 [0·06-0·15], I2=90·5%), and pace of ageing (five studies; n=7895; 0·10 [0·01-0·19], I2=91·0%) were significantly associated with higher frailty. In longitudinal meta-analyses, higher GrimAge EAA (five studies; n=6143; 0·02 [0·00-0·05], I2=46·0%, p=0·0481) was significantly associated with increases in frailty, whereas PhenoAge EAA and pace of ageing were not significantly associated with frailty. INTERPRETATION: Higher GrimAge EAA is consistently associated with higher frailty. Future research should focus on developing and validating DNA methylation clocks that integrate molecular surrogates of health risk and are specifically trained to predict frailty in large, harmonised, longitudinal cohorts, enabling their translation into clinical practice. FUNDING: National University of Singapore.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Tay JH, Barros D, Wang W, et al. Biological age measured by DNA methylation clocks and frailty: a systematic review and meta-analysis. Lancet Healthy Longev. 2025. PMID: 41207303. doi:10.1016/j.lanhl.2025.100773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。